Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns

George Sgouros, Yuni K. Dewaraja, Freddy Escorcia, Stephen A. Graves, Thomas A. Hope, Amir Iravani, Neeta Pandit-Taskar, Babak Saboury, Sara St James, Pat B. Zanzonico

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Radiopharmaceutical therapy (RPT) is defined as the delivery of radioactive atoms to tumor-associated targets. In RPT, imaging is built into the mode of treatment since the radionuclides used in RPT often emit photons or can be imaged using a surrogate. Such imaging may be used to estimate tumor-absorbed dose. We examine and try to elucidate those factors that impact the absorbed dose-versus-response relationship for RPT agents. These include the role of inflammation- or immune-mediated effects, the significance of theranostic imaging, radiobiology, differences in dosimetry methods, pharmacokinetic differences across patients, and the impact of tumor hypoxia on response to RPT.

Original languageEnglish
Pages (from-to)12S-22S
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume62
DOIs
StatePublished - Dec 1 2021

Keywords

  • dosimetry
  • imaging
  • radionuclide therapy
  • radiopharmaceutical therapy
  • radiopharmaceuticals
  • theranostics

Fingerprint

Dive into the research topics of 'Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns'. Together they form a unique fingerprint.

Cite this